Cero Therapeutics agrees to sell operating unit to SRX Global for stock, debt cancellation

PUBT · 1d ago
Cero Therapeutics agrees to sell operating unit to SRX Global for stock, debt cancellation
  • SRX Global agreed to buy all shares of Cero Therapeutics, the operating subsidiary of Cero Therapeutics Holdings.
  • Consideration includes SRX common stock valued at USD 1 million, set using the lower of the prior close or 20-day VWAP.
  • SRX will cancel Cero’s Consolidated Senior Secured Promissory Note, up to USD 11.67 million principal; USD 8.25 million outstanding.
  • Buyer will assume about USD 1.56 million of specified liabilities, with related indemnities for Holdings directors and officers.
  • Deal includes a 30-day go-shop; a Superior Proposal must be executable and close no later than March 15, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-107410), on October 07, 2026, and is solely responsible for the information contained therein.